Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin.

Published on Jan 18, 2018in Therapeutic Advances in Gastroenterology3.52
· DOI :10.1177/1756283X17744739
Y. Derwa4
Estimated H-index: 4
(University of Leeds),
Christopher J.M. Williams4
Estimated H-index: 4
(University of Leeds)
+ 6 AuthorsDavid J. Gracie16
Estimated H-index: 16
(University of Leeds)
Sources
Abstract
Objectives: Patient-reported symptoms correlate poorly with mucosal inflammation. Clinical decision-making may, therefore, not be based on objective evidence of disease activity. We conducted a study to determine factors associated with clinical decision-making in a secondary care inflammatory bowel disease (IBD) population, using a cross-sectional design. Methods: Decisions to request investigations or escalate medical therapy were recorded from outpatient clinic encounters in a cohort of 276 patients with ulcerative colitis (UC) or Crohn’s disease (CD). Disease activity was assessed using clinical indices, self-reported flare and faecal calprotectin ≥ 250 µg/g. Demographic, disease-related and psychological factors were assessed using validated questionnaires. Logistic regression was performed to determine the association between clinical decision-making and symptoms, mucosal inflammation and psychological comorbidity. Results: Self-reported flare was associated with requesting investigations in CD [odds ratio (OR) 5.57; 95% confidence interval (CI) 1.84-17.0] and UC (OR 10.8; 95% CI 1.8-64.3), but mucosal inflammation was not (OR 1.62; 95% CI 0.49-5.39; and OR 0.21; 95% CI 0.21-1.05, respectively). Self-reported flare (OR 7.96; 95% CI 1.84-34.4), but not mucosal inflammation (OR 1.67; 95% CI 0.46-6.13) in CD, and clinical disease activity (OR 10.36; 95% CI 2.47-43.5) and mucosal inflammation (OR 4.26; 95% CI 1.28-14.2) in UC were associated with escalation of medical therapy. Almost 60% of patients referred for investigation had no evidence of mucosal inflammation. Conclusions: Apart from escalation of medical therapy in UC, clinical decision-making was not associated with mucosal inflammation in IBD. The use of point-of-care calprotectin testing may aid clinical decision-making, improve resource allocation and reduce costs in IBD.
📖 Papers frequently viewed together
3 Citations
15 Citations
21 Citations
References33
Newest
#1David J. Gracie (University of Leeds)H-Index: 16
#2Christopher J.M. Williams (St James's University Hospital)H-Index: 4
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 7 authors...
Background & Aims Symptoms compatible with irritable bowel syndrome (IBS) are common in patients with inflammatory bowel disease (IBD), but it is unclear whether this relates to occult IBD activity. We attempted to resolve this issue in a secondary care population by using a cross-sectional study design. Methods We analyzed Rome III IBS symptoms, disease activity indices, and psychological, somatization, and quality of life data from 378 consecutive, unselected adult patients with IBD seen in cl...
49 CitationsSource
#1Fernando Gomollón (University of Zaragoza)H-Index: 37
#2Axel DignassH-Index: 46
Last. Paolo Gionchetti (University of Zaragoza)H-Index: 80
view all 23 authors...
This paper is the first in a series of two publications relating to the European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on the diagnosis and management of Crohn’s disease and concerns the methodology of the consensus process, and the classification, diagnosis and medical management of active and quiescent Crohn’s disease. Surgical management as well as special situations including management of perianal Crohn’s disease of this ECCO Consensus are covered in a subsequent ...
987 CitationsSource
#1David J. Gracie (St James's University Hospital)H-Index: 16
#2Christopher J.M. Williams (St James's University Hospital)H-Index: 4
Last. Alexander C. Ford (St James's University Hospital)H-Index: 86
view all 7 authors...
Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease
75 CitationsSource
#1Udai P. Singh (USC: University of South Carolina)H-Index: 36
#2Narendra P. Singh (USC: University of South Carolina)H-Index: 29
Last. Prakash S. Nagarkatti (USC: University of South Carolina)H-Index: 72
view all 7 authors...
Abstract Crohn’s disease (CD) and ulcerative colitis (UC), two forms of inflammatory bowel disease (IBD), are chronic, relapsing, and tissue destructive lesions that are accompanied by the uncontrolled activation of effector immune cells in the mucosa. Recent estimates indicate that there are 1.3 million annual cases of IBD in the United States, 50% of which consists of CD and 50% of UC. Chemokines and cytokines play a pivotal role in the regulation of mucosal inflammation by promoting leukocyte...
124 CitationsSource
#1Elena CerrilloH-Index: 9
#2Belén BeltránH-Index: 30
Last. Pilar NosH-Index: 29
view all 8 authors...
BACKGROUND: Magnetic resonance enterography (MRE) is an effective method of assessing small bowel Crohn's disease (CD). Fecal calprotectin (FC) correlates well with endoscopic disease activity. We aimed to evaluate the correlation between FC and disease activity according to MRE and surgical pathology in small bowel CD. METHODS: One hundred twenty consecutive patients with ileal CD who underwent MRE assessment were included. Clinical data, C-reactive protein and FC, radiological and histological...
41 CitationsSource
#1Laura E. Targownik (UM: University of Manitoba)H-Index: 40
#2Kathryn A. Sexton (UM: University of Manitoba)H-Index: 8
Last. Lesley A. Graff (UM: University of Manitoba)H-Index: 35
view all 7 authors...
The Relationship Among Perceived Stress, Symptoms, and Inflammation in Persons With Inflammatory Bowel Disease
90 CitationsSource
#1Gerhard Rogler (UZH: University of Zurich)H-Index: 89
#2Stephan R. Vavricka (UZH: University of Zurich)H-Index: 43
: It is generally agreed that environmental factors trigger the onset and cause flares of inflammatory bowel disease. Although we have learned much about genetic susceptibility factors of inflammatory bowel disease in recent years, our knowledge on these environmental factors is limited. The sum of all environmental factors a human is exposed to during lifetime has been termed the exposome. The challenge of investigating the exposome is discussed in this overview. The environmental exposure of a...
71 CitationsSource
#1Nicolas Williet (Nancy-Université)H-Index: 16
#2William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
Last. Laurent Peyrin Biroulet (Nancy-Université)H-Index: 12
view all 3 authors...
The Food and Drug Administration (FDA) is moving from the Crohn's Disease Activity Index to patient-reported outcomes (PROs) and objective measures of disease, such as findings from endoscopy. PROs will become an important aspect of assessing activity of inflammatory bowel disease (IBD) and for labeling specific drugs for this disease. PROs always have been considered in the management of patients with rheumatoid arthritis or multiple sclerosis, and have included measurements of quality of life,...
165 CitationsSource
#1Jin-Feng Lin (Southern Medical University)H-Index: 1
#2Chen Jinmin (Southern Medical University)H-Index: 1
Last. Bo Jiang (Southern Medical University)H-Index: 1
view all 8 authors...
Abstract Fecal calprotectin (FC) is a promising biomarker for diagnosis of inflammatory bowel disease (IBD). However, the utility of FC for assessment of IBD activity has yet to be clearly demonstrated. The aim of our study was to evaluate the diagnostic accuracy of FC for differentiating between patients with active IBD and those in remission. We systematically searched the databases Medline, Web of Science, Cochrane Library, and EMBASE for eligible studies from December 2013 or earlier that ev...
189 CitationsSource
#1Gerhard RoglerH-Index: 89
#2Xavier AldeguerH-Index: 1
Last. Robert Logan (King's College)H-Index: 8
view all 11 authors...
Inflammatory bowel diseases (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD) are organic inflammatory diseases, caused by chronic mucosal inflammation of the intestine. They are typically characterized by variable disease activity, often with repeated periods of intermittent disease activity and remission. Irritable bowel syndrome (IBS) is a non-inflammatory functional disorder and, by definition, presumes the absence of organic disease.1 As the presenting manifestations of IBD an...
34 CitationsSource
Cited By13
Newest
#1Nurulamin M Noor (UCL: University College London)H-Index: 6
Last. Xavier RoblinH-Index: 51
view all 4 authors...
Despite huge advances in understanding the molecular basis of IBD, clinical management has continued to rely on a "trial and error" approach. In addition, a therapeutic ceiling has emerged whereby even the most effective interventions are only beneficial for approximately 30% of patients. Consequently, several tools have been developed to aid stratification and guide treatment-decisions. We review the potential application for many of these precision medicine approaches, which are now almost wit...
Source
#1Keeley M. Fairbrass (University of Leeds)H-Index: 2
#2David J. Gracie (University of Leeds)H-Index: 16
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 3 authors...
BACKGROUND Psychological co-morbidity is more common in patients with inflammatory bowel disease (IBD), compared with the general population, but little is known about the cumulative effect of increasing psychological burden on disease behaviour. AIMS To examine the effect of psychological co-morbidity on inflammatory bowel disease in a longitudinal follow-up study. METHODS We collected complete demographic, symptom and psychological co-morbidity data (anxiety, depression and somatisation scores...
Source
#1Keeley M. Fairbrass (St James's University Hospital)H-Index: 2
#2David J. Gracie (St James's University Hospital)H-Index: 16
Source
#1Matthew D. Coates (PSU: Pennsylvania State University)H-Index: 3
#2Ansh Johri (PSU: Pennsylvania State University)H-Index: 3
Last. Kofi Clarke (PSU: Pennsylvania State University)H-Index: 8
view all 12 authors...
OBJECTIVES Inflammation is an important driver of abdominal pain in inflammatory bowel disease (IBD). However, some patients in remission still experience pain. We aimed to identify risk factors associated with abdominal pain in quiescent IBD (QP-IBD) and to characterize differences from patients with active disease experiencing pain (AP-IBD). METHODS We performed a retrospective analysis utilizing data from our institution's IBD Natural History Registry (January 1, 2015-August 31, 2018). Endosc...
1 CitationsSource
#1Keeley M. Fairbrass (University of Leeds)H-Index: 2
#2Sarah J Costantino (St James's University Hospital)H-Index: 1
Last. Alexander C. Ford (St James's University Hospital)H-Index: 86
view all 4 authors...
Summary Background Patients with inflammatory bowel disease (IBD) often report symptoms compatible with irritable bowel syndrome (IBS), which might have an effect on psychological health. However, previous estimates of the magnitude of this issue have not accounted for ongoing inflammation as the potential cause. We updated a previous systematic review and meta-analysis to determine prevalence of IBS-type symptoms in patients with IBD in remission to better quantify the magnitude of this issue. ...
20 CitationsSource
#1Nurulamin M Noor (University of Cambridge)H-Index: 6
#2Ailsa HartH-Index: 57
Last. Tim Raine (University of Cambridge)H-Index: 27
view all 6 authors...
There have been immediate and profound impacts of SARS-CoV-2 and COVID-19 on healthcare services worldwide with major consequences for non-COVID-19 related healthcare. Alongside efforts to reconfigure services and enable continued delivery of safe clinical care for patients with IBD, consideration must also be given to management of IBD research activity. In many centres there has been an effective shutdown of IBD clinical trial activity as research sites have switched focus to either COVID-19 r...
7 CitationsSource
#1Fernando Bermejo (URJC: King Juan Carlos University)H-Index: 33
#2Alicia Algaba (Hospital Universitario La Paz)H-Index: 19
Last. Iván Guerra (Hospital Universitario La Paz)H-Index: 16
view all 8 authors...
Resumen Introduccion La calprotectina en heces es una tecnica util para detectar actividad en pacientes con colitis ulcerosa. No obstante, puede haber valores elevados debido a otros factores distintos de la actividad de la colitis ulcerosa. Nuestro objetivo fue analizar posibles resultados falsos positivos de calprotectina para la actividad de la colitis ulcerosa debidos a la presencia de polipos inflamatorios. Pacientes y metodos Estudio retrospectivo, descriptivo y observacional. Se recogiero...
Source
#1Fernando Bermejo (URJC: King Juan Carlos University)H-Index: 33
#2Alicia Algaba (Hospital Universitario La Paz)H-Index: 19
Last. Iván Guerra (Hospital Universitario La Paz)H-Index: 16
view all 8 authors...
Resumen Introduccion La calprotectina en heces es una tecnica util para detectar actividad en pacientes con colitis ulcerosa. No obstante, puede haber valores elevados debido a otros factores distintos de la actividad de la colitis ulcerosa. Nuestro objetivo fue analizar posibles resultados falsos positivos de calprotectina para la actividad de la colitis ulcerosa debidos a la presencia de polipos inflamatorios. Pacientes y metodos Estudio retrospectivo, descriptivo y observacional. Se recogiero...
Source
#1Anna Luisa BatheH-Index: 1
#2Eirini MavropoulouH-Index: 3
Last. Ahmad AmanzadaH-Index: 10
view all 7 authors...
Background Faecal calprotectin (FC) seems to be the best available biomarker for the detection of intestinal inflammation in patients with inflammatory bowel disease (IBD). The aim of this study is to clarify whether the measurement of FC has changed the number of ultrasound and endoscopic procedures, drug modifications, as well as FC re-measurements in IBD patients.
2 CitationsSource
BACKGROUND Inflammatory bowel diseases (IBD) have been associated with a low quality of life (QoL) and a negative impact on work productivity compared to the general population. Information about disease control, patient-reported outcomes (PROs), treatment patterns and use of healthcare resources is relevant to optimizing IBD management.
17 CitationsSource